Ringpu Bio obtains approval for cat deworming drug

Tianjin Ringpu Bio-Technology (SZSE:300119) announced that its wholly-owned subsidiary, Ringpu (Tianjin) Biopharmaceutical Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs for its cat deworming drug. The approved product, Milbemycin Oxime Praziquantel Tablets (for cats), is a broad-spectrum anthelmintic effective against common parasites like tapeworms, roundworms, and hookworms. The company emphasizes the drug's safety, efficacy, and suitability for the local cat population, aligning with the growing demand for domestic pet healthcare solutions. This approval signifies a key advancement in Ringpu Bio's strategic focus on the pet medicine sector, particularly in light of the current reliance on imported medications. The company aims to further invest in research and development to address unmet clinical needs and expand its presence in both domestic and international markets.